Clinical Trial Update: The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) study, completed, in patients with metabolic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• FENOFIBRATE (Fenofibrate)
• metformin (metformin)

Snippet

Sponsor: University of Pennsylvania | Conditions: Metabolic Syndrome x | Phase 2 | Status: COMPLETED